7/102 sources · 2 publishersUpdated Oct 8, 22:26 UTC
AbbVie’s epcoritamab plus R‑CHOP cuts progression risk in diffuse large B‑cell lymphoma
AbbVie reported that its late‑stage trial of epcoritamab combined with R‑CHOP lowered the risk of disease progression or death by 51% versus R‑CHOP alone in patients with diffuse large B‑cell lymphoma. The study showed a hazard ratio of 0.49 with a statistically significant p‑value below 0.0001. AbbVie’s share price rose 0.3% to $266.63 on the news. The company and partner Genmab said they will begin regulatory discussions following the data.
Why it matters
AbbVie plans regulatory discussions based on the trial results, which could lead to approval and sales of epcoritamab, potentially boosting future revenue.
Key facts
- 1AbbVie’s stock rose 0.3% to $266.63 on Oct. 6. gurufocus.com
- 2The trial showed a 51% reduction in disease progression risk when epcoritamab was added to R‑CHOP. gurufocus.com
- 3Hazard ratio for progression or death was 0.49 with a p‑value below 0.0001. finance.yahoo.com
- 4The study enrolled patients with diffuse large B‑cell lymphoma. gurufocus.com
- 5AbbVie and partner Genmab plan regulatory discussions and future presentations. gurufocus.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.